<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 33-year-old patient suffered from recurring <z:chebi fb="6" ids="22696">Beh</z:chebi>,cet's <z:hpo ids='HP_0002583'>colitis</z:hpo> despite treatment with <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and later cyclosporin </plain></SENT>
<SENT sid="1" pm="."><plain>The patient was then successfully shifted from cyclosporin, a T-cell specific <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi>, to <z:chebi fb="0" ids="29013">fusidic acid</z:chebi> treatment (500 mg t.i.d.) </plain></SENT>
<SENT sid="2" pm="."><plain>During <z:chebi fb="0" ids="29013">fusidic acid</z:chebi> treatment, he went into complete remission, and his <z:chebi fb="2" ids="8378">prednisolone</z:chebi> dose could be reduced from 30 to 5 mg/day </plain></SENT>
<SENT sid="3" pm="."><plain>The case report substantiates recent in vitro data indicating that <z:chebi fb="0" ids="29013">fusidic acid</z:chebi> has a similar effect on T-cell function as cyclosporin </plain></SENT>
<SENT sid="4" pm="."><plain>It is suggested that the effect of <z:chebi fb="0" ids="29013">fusidic acid</z:chebi> in other <z:hpo ids='HP_0011010'>chronic</z:hpo> immunoinflammatory diseases should be examined </plain></SENT>
</text></document>